Abbott Pandemic Defense Coalition
Abbott has been transforming diagnostics since 1972, delivering solutions for urgent global health needs. For decades we have been investing in collaborative work that enables reliable pathogen detection, a critical component to connect patients to care.
The mission?
To help end infectious disease epidemics while also trying to help stop future pandemics.
Photo: Dr. Mary Rodgers, Infectious Disease Scientist at Abbott, pulling samples for research from one of many freezers at Abbott's R&D headquarters in the US.
Expanding on the surveillance program, Abbott is now also looking for new and emerging pathogens through the Abbott Pandemic Defense Coalition.
The program is the first-of-its-kind industry-led global network that is dedicated to identifying, tracking and responding to disease outbreaks. This private-public collaboration is helping scientists, healthcare providers and communities stay one step ahead of viral threats.
With a new threat identified, Coalition partners coordinate closely, determining if similar cases are appearing elsewhere. Where needed, we work to develop and deploy research use tests quickly to understand the risk level and pandemic potential.
from patients that have a suspected infectious disease illness
speeding up detection of new variants and pathogens
enabling a global response when threats emerge
helping public health agencies protect communities
Real progress requires strong collaborations. Through our network of partners:
Together, we’re closing gaps in detection and diagnosis to help safeguard global health.
“Viruses do change. Viruses do mutate. Even for viruses like HIV and hepatitis that have been around for a long time. Whatever happens in one part of world, we should keep an eye out on it, because it may end up moving to another part of the world.”
Alhaji Njai
Senior Scientist and Associate Professor, Infectious Diseases, Immunology, Toxicology, University of Sierra Leone,
Sierra Leone
“One thing we have learned from COVID is the speed in which you can identify something that is upcoming, something that has pandemic potential. And that speed will only come if we as scientists collaborate with each other.”
Erum Khan
Professor and Chair Department of Pathology and Laboratory Medicine,
The Aga Khan University,
Pakistan
“I think the Abbott Pandemic Defense Coalition is going to make huge in-roads into global health and identifying the next potential pandemic. Being part of this Coalition to me is one of the most exciting things that I am doing in my lab.”
PJ Utz
Professor of Medicine, Immunology and Rheumatology,
Stanford University,
USA
In 2019, Abbott discovered HIV-1 Group M, subtype L (the first new HIV subtype identified in 20 years)1
More than half of the known rare strains of HIV have been identified by Abbott2
Abbott partnered with the country of Georgia and NCDC, an Abbott Pandemic Defense Coalition partner on the world’s first hepatitis C elimination program, decreasing disease prevalence in the country by 67%3
Abbott utilized diverse samples collected in the development of next-generation assays for hepatitis B to enable superior mutant detection4
Several of the most significant SARS-CoV-2 variants of concern were identified by Abbott Pandemic Defense Coalition partners5
The Abbott Pandemic Defense Coalition has identified more than 20 new viruses that are currently under investigation and developed more than 40 new research use tests to track the prevalence of pathogens making patients ill2
The Abbott Pandemic Defense Coalition has uncovered significant outbreaks–including Oropouche,6 Mayaro,7 and yellow fever viruses8 in Colombia, hepatitis E virus9 in South Sudan, and anthrax10 in Uganda
The Abbott Pandemic Defense Coalition has trained more than 100 future virus hunters—building the future workforce that may protect the generations to come
Showcase of our latest findings
A closer look into the work we are leading with our partners
Solutions that deliver reliable results for clinical decision-making and patient outcomes.
Comprehensive viral load testing with access, efficiency, and global insight.
Point of care solutions for key health and therapeutic areas – putting answers in your hands.
Every unit counts to deliver safe blood and plasma products.
Sign up to learn more about our latest insights, updates, and innovations. Submit your information below, and stay informed about the work from our global virus hunters.
For in vitro diagnostic use. All ARCHITECT analyzers are Class I laser products.
Testimonials herein are solicited. The testimonials are representative of customer experience. Experience will be unique and individual to each customer.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
